INTRODUCTION
Biopharmaceuticalindustry ofChinadeveloped behind the leading countries, however, it is growing dramaticallyfast during past decades. Chinese government invested in biopharmaceuticals, aswell as made the supporting policies. At present, biopharmaceutical industry isone of the leading industries inChina.
There were 36 listedbiopharmaceutical companies in 2015, the volume of sales reached RMB50.59billion, and the net profit obtained RMB9.24 billion.
Keep pace with thedevelopment of latest biopharmaceutical technologies, this industry dominatedthe whole pharmaceutical industry. Meanwhile, the awareness of health lifestyle of people has changed a lot, which focuses much more on preventionsinstead of therapy treatments. Those factors become incentives to the progressof biopharmaceutical enterprises.
1) TheAim of this report
n To provide readers with comprehensive & in-depthunderstanding ofChina’sbio-pharmaceutical industry;
n To understand the development situation ofbio-pharmaceutical industry inChina;
n Get more information of the major bio-pharmaceuticalproducers inChina;
n Gain insight into the major bio-pharmaceutical producersabout operation;
n To predict what future ofChinabio-pharmaceutical industrywill be;
n To reveal opportunities inChinabio-pharmaceutical industry.
2) Benefitfrom the report
n Financial performance in 2015 and YoY changes, includingrevenue, operating profit, net profit, revenue and gross profit margin frombio-pharmaceutical business;
n Changes of revenue and net profit in the latest five yearsand the reasons;
n Adjustment to business structure in the recent 2-3 years;
n Development strategy anddevelopment trends in the near future.
3) Deliverables
PDF-formatreport, with around 30-50 pages.
4) Timeneeded
Three working days needed.
Part | Contents |
1 | Executive summary |
2 | Ranking of main listed domestic bio-pharmaceutical enterprises in 2015 |
2.1 | List ofChina’s listed bio-pharmaceutical enterprises |
2.2 | By revenue |
2.3 | By net profit |
2.4 | By total assets |
2.5 | By revenue and gross profit margin of bio-pharmaceutical business |
2.6 | By operating profit |
2.7 | By primary earnings per share |
3 | Analysis of listed bio-pharmaceutical enterprises |
3.1 | Jiangsu Sihuan Bioengineering Co., LTD |
3.2 | Hualan Biological Engineering, Inc. |
3.3 | Guilin Layn Natural Ingredients Corp. |
3.4 | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. |
3.5 | Jiangxi Boya Bio-pharmaceutical Co., Ltd. |
3.6 | Beijing Strong Biotechnologies, Inc. |
3.7 | Beijing Tiantan Biological Products Corporation Limited |
3.8 | China Animal Husbandry Industry Co., Ltd. |
3.9 | Shanghai Jiaoda Onlly Co.,Ltd. |
3.10 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. |
3.11 | Shanghai RAAS Blood Products Co., Ltd. |
3.12 | Beijing SL Pharmaceutical Co., Ltd. |
3.13 | Changchun High and New Technology Industry (Group) Inc. |
3.14 | Shenzhen Neptunus Bioengineering Co., Ltd. |
3.15 | Tonghua Dongbao Pharmaceutical Co., Ltd. |
3.16 | Changsheng Bio-technology Co., Ltd. |
3.17 | Sichuan Maccura Biotechnology Co., Ltd. |
3.18 | Zhongyuan Union Cell & Gene Engineering Grop., Ltd. |
3.19 | Shanghai Kehua Bioengineering Co., Ltd. |
3.20 | Staidson (Beijing) Biopharmaceuticals Co., Lt |
3.21 | Chongqing Zhifei Biological Products Co., Ltd. |
3.22 | Beijing Leadman Biochemistry Co., Ltd. |
3.23 | Ningbo Medicalsystem Biotechnology Co., Ltd. |
3.24 | Anhui Anke Biotechnology (Group) Co., Ltd. |
3.25 | Guangzhou Wondfo Biotech Co., Ltd. |
3.26 | Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. |
3.27 | Da An Gene Co., Ltd. ofSunYat-senUniversity |
3.28 | Fujian Cosunter Pharmaceutical Co., Ltd. |
3.29 | Guangdong Vtr Bio-Tech Co., Ltd. |
3.30 | Zhong Zhu Holding Co., Ltd. |
3.31 | Zhenxing Biopharmaceutical and Chemical Co., Ltd. |
3.32 | Zhejiang Qianjiang Biochemical Co., Limited |
3.33 | Ginwa Enterprise (Group) Inc. |
3.34 | Shenzhen Cau Technology Co., Ltd. |
3.35 | Baotou Dongbao Bio-tech Co., Ltd. |
3.36 | Walvax Biotechnology Co., Ltd. |
本报告所有内容受法律保护,中华人民共和国涉外调查许可证:国统涉外证字第1454号。 本报告由中商产业研究院出品,报告版权归中商产业研究院所有。本报告是中商产业研究院的研究与统计成果,报告为有偿提供给购买报告的客户内部使用。未获得中商产业研究院书面授权,任何网站或媒体不得转载或引用,否则中商产业研究院有权依法追究其法律责任。如需订阅研究报告,请直接联系本网站,以便获得全程优质完善服务。 本报告目录与内容系中商产业研究院原创,未经本公司事先书面许可,拒绝任何方式复制、转载。 在此,我们诚意向您推荐鉴别咨询公司实力的主要方法。
2024年9月9日,中商产业董事长、研究院执行院长杨云(客座教授)为贵州省贵阳市作《新规后如何高质量招商》...
2024年9月9日,中商产业董事长、研究院执行院长杨云(客座教授)为贵州省贵阳市作《新规后如何高质量招商》...
查看详情9月8日,2024中国产业转移发展对接活动(云南)在昆明滇池国际会展中心拉开帷幕,为充分利用产业转移发展对...
9月8日,2024中国产业转移发展对接活动(云南)在昆明滇池国际会展中心拉开帷幕,为充分利用产业转移发展对...
查看详情近日,中商产业研究院专家团队赴甘肃省张掖市开展《张掖市产业集群培育提升规划》项目调研工作。调研期间,...
近日,中商产业研究院专家团队赴甘肃省张掖市开展《张掖市产业集群培育提升规划》项目调研工作。调研期间,...
查看详情近日,中商产业研究院专家团队赴福建省宁德市开展《“十五五”时期宁德市面临的形势、阶段性特征和发展路径...
近日,中商产业研究院专家团队赴福建省宁德市开展《“十五五”时期宁德市面临的形势、阶段性特征和发展路径...
查看详情2024年8月29日上午,中商产业董事长、研究院执行院长杨云(客座教授)为四川省德阳市作《新形势下如何高质...
2024年8月29日上午,中商产业董事长、研究院执行院长杨云(客座教授)为四川省德阳市作《新形势下如何高质...
查看详情2024年8月25日,山西省发展和改革委员会组织召开“十五五”规划前期研究课题预评审汇报会。中商产业研究院...
2024年8月25日,山西省发展和改革委员会组织召开“十五五”规划前期研究课题预评审汇报会。中商产业研究院...
查看详情近日,中商产业研究院专家团队赴安徽省滁州市开展《“十五五”时期滁州市培育发展新质生产力,加快现代产业...
近日,中商产业研究院专家团队赴安徽省滁州市开展《“十五五”时期滁州市培育发展新质生产力,加快现代产业...
查看详情2024年8月20日,河北省发展和改革委员会组织召开“十五五”规划重点研究课题中期成果汇报会。中商产业研究...
2024年8月20日,河北省发展和改革委员会组织召开“十五五”规划重点研究课题中期成果汇报会。中商产业研究...
查看详情